Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK

PharmacoEconomics

Volumn 20, Issue 4, 2002, Pages 279-287

  Wahlqvist, P ^a   Junghard, O ^a   Higgins, A ^b   Green, J ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; HEALTH CARE COST; HUMAN; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PROBABILITY; REFLUX ESOPHAGITIS; TREATMENT FAILURE; UNITED KINGDOM;

EID: 0036245603     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220040-00006     Document Type: Article

References (33)

1. Epidemiology and natural history of gastro-oesophageal reflux disease
2. Gastro-oesophageal reflux disease in general practice
3. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis
4. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice
5. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
6. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification
7. Efficacy and safety of lansoprazole in the treatment of erosive reflux oesophagitis
8. Pantoprazole and omeprazole in the treatment of reflux esophagitis: A European multicentre study
9. Omeprazole or ranitidine in long-term treatment of reflux esophagitis
10. Lansoprazole 15 and 30mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis
11. A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis: A multicentre trial
12. Lansoprazole 30mg versus omeprazole 40mg in the treatment of reflux oesophagitis grade II, III and IV A (a Dutch multicentre trial)
13. Economic evaluation of long-term management strategies for erosive oesophagitis
14. Management of gastro-oesophageal reflux disease in general practice
15. An evidence-based appraisal of reflux disease management: The General Workshop Report
16. Esomeprazole 40 mg provides more effective acid control that standard doses of all other proton pump inhibitors
17. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomised controlled trial
18. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial
19. Läkemedelsmonografier -nexium (esomeprazol)
20. Life Table analysis
21. Management of GORD in the UK: Results of a survey
22. Cost effectiveness of omeprazole in the treatment of reflux oesophagitis
23. A one year model for the cost effectiveness of treating reflux esophagitis
24. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs Survey
25. The impact of gastrooesophageal reflux disease on health-related quality of life
26. Clinical effectiveness and quality of life with ranitidine vs placebo in gastrooesophageal reflux disease patients: A clinical experience network (CEN) study
27. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine: Results from a multi-center clinical trial
28. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organisation
29. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD): Results from a cross-sectional study